Recursion Pharmaceuticals Inc (RXRX) financials · rev $74.7M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Recursion Pharmaceuticals Inc (RXRX) rev $74.7M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $74.7M | $58.8M |
| Cost of Revenue | $71.0M | $45.2M |
| Gross Profit | $3.73M | $13.6M |
| Operating Income | -$648.1M | -$479.0M |
| Net Income | -$644.8M | -$463.7M |
| EPS (Diluted) | -$1.44 | -$1.69 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.47B | $1.45B |
| Current Assets | $812.8M | $714.3M |
| Cash & Equivalents | $743.3M | $594.4M |
| PP&E | $103.9M | $141.1M |
| Total Liabilities | $343.3M | $413.8M |
| Current Liabilities | $147.7M | $187.5M |
| Total Debt | $9.56M | $19.0M |
| Shareholders' Equity | $1.13B | $1.03B |
| Retained Earnings | -$2.08B | -$1.43B |
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$371.8M | -$359.2M |
| CapEx | $6.47M | $13.7M |
| Investing Cash Flow | -$16.9M | $260.1M |
| Financing Cash Flow | $521.5M | $304.1M |
| Net Change in Cash | $150.9M | $201.6M |
| Free Cash Flow | -$378.3M | -$372.9M |
FAQ
What is RXRX P/E and revenue?
Recursion Pharmaceuticals Inc (RXRX) rev $74.7M.
What is RXRX revenue?
Recursion Pharmaceuticals Inc last cached revenue is $74.7M (FY2025).
Is RXRX profitable?
Recursion Pharmaceuticals Inc last cached net income is -$644.8M (FY2025).
What are RXRX total assets?
Recursion Pharmaceuticals Inc last cached total assets are $1.47B (FY2025).
What is RXRX free cash flow?
Recursion Pharmaceuticals Inc last cached free cash flow is -$378.3M (FY2025).
Not investment advice. Cached statements, not a live tape.